- Vera Therapeutics will present data from the **ORIGIN Phase 3 clinical trial of atacicept** for IgA nephropathy (IgAN) as a featured late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2025 on **November 6, 2025**.  **[1831828_36ed2dddfd9b4bb1b322a0f983b39a8b_0]** 
- The **ORIGIN Phase 3 trial met its primary endpoint** with a statistically significant and clinically meaningful reduction in proteinuria at week 36 in the prespecified interim analysis.  **[1831828_36ed2dddfd9b4bb1b322a0f983b39a8b_1]** 
- Atacicept has received **FDA Breakthrough Therapy Designation** for the treatment of IgAN, based on data from the ORIGIN Phase 2b clinical trial.  **[1831828_36ed2dddfd9b4bb1b322a0f983b39a8b_1]** 
- Vera Therapeutics believes atacicept is positioned for **best-in-class potential**, targeting B cells to reduce autoantibodies.  **[1831828_36ed2dddfd9b4bb1b322a0f983b39a8b_1]**

Vera Therapeutics (VERA)